This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novartis Answers Critics

NEW YORK ( TheStreet) -- With shares of Merck (MRK), Bristol-Myers Squibb (BMY - Get Report) and Pfizer (PFE) all trading at or near their 52-week highs, there aren't many bargains left in pharmaceutical stocks. But Novartis (NVS - Get Report), despite its 32% year-to-date gains, might be a worthwhile exception heading as we head into 2014.

While I do believe threats to the company's pipeline -- specifically from generic competition -- remain valid concerns, I believe the Street has exaggerated fears about margin pressure and the impact it would have on the company's branded drugs business. Given management's recent moves to mitigate pipeline worries, investors would do well by placing a bet here on one of the best names in Big Pharma.

Follow this sector long enough and you will come to appreciate that a company's product pipeline is its lifeblood. If the pipeline is considered weak relative to its peers, the Street will question management's commitment to long term growth, which is often punishable by a low P/E and estimate cuts. This, then, forces the company to push research and development spending higher - in a way to keep its "blood levels up."

As bad as that might appear, the biggest fear, though, is when a company approaches what is called a "patent cliff." This occurs when popular drugs lose their patents, which then opens the floodgates to generic competition, or non-branded alternatives that are often cheaper. Although Novartis has yet to feel adverse effects, the risk to drugs like Diovan, which brings in more than $4 billion in annual sales for Novartis, remains an overhang.

When this happens, and assuming that this expiring patent can't be offset by other strong-selling products within the pipeline, the Street loses faith that the company can support both its current dividend or future cash flow allocations. I don't need to tell you what can happen to a company's stock price. It's not pretty.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BMY $66.72 1.10%
NVS $98.54 0.01%
AAPL $126.62 1.70%
FB $87.41 1.90%
GOOG $525.42 0.75%

Markets

DOW 17,795.83 +176.32 1.00%
S&P 500 2,063.11 +5.47 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs